Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Inclusion Criteria: * Patient is currently participating in a Global Novartis-sponsored study receiving osilodrostat for any type of endogenous CS and has fulfilled all their requirements in the parent study. * Patient is currently benefiting from treatment with osilodrostat, as determined by the Investigator. * Patient has demonstrated compliance, as assessed by the Investigator, with the parent study protocol requirements. * Willingness and ability to comply with scheduled visits and treatment plans. * Written informed consent obtained prior to enrolling into the roll-over study before evaluating the applicability of the subject's participating in the study. -- If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness. Exclusion Criteria: * Patient has been permanently discontinued from osilodrostat study treatment in a parent Novartis-sponsor study. * Patients who are receiving osilodrostat in combination with unapproved or experimental treatments for any type of endogenous CS. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. Pregnant or nursing (lactating) women * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 wee…